Editorial: Translation of health technology reassessment and its outputs of disinvestment, de-implementation and de-adoption of drugs and medical devices in practice-what have we learned?

Схожие документы

• Editorial: Translation of health technology reassessment and its outputs of disinvestment, de-implementation and de-adoption of drugs and medical devices in practice-what have we learned?
  по: Rosmin Esmail, и др.
  Опубликовано: (2025-10-01)
• Editorial: Pharmacoeconomics in the era of health technology assessment and outcomes research to prioritize resource use, innovation and investment
  по: François R. Girardin, и др.
  Опубликовано: (2023-05-01)
• Using clinical practice variations as a method for commissioners and clinicians to identify and prioritise opportunities for disinvestment in health care: a cross-sectional study, systematic reviews and qualitative study
  по: William Hollingworth, и др.
  Опубликовано: (2015-04-01)
• Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group
  по: Wei Fang Dai, и др.
  Опубликовано: (2021-10-01)
• Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise
  по: Wei Fang Dai, и др.
  Опубликовано: (2021-11-01)